BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
Rhea-AI Summary
BioMarin (NASDAQ: BMRN) announced that Alexander Hardy, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 11:15 am PT / 2:15 pm ET in San Francisco.
The company plans to announce certain preliminary financial results for the year ended December 31, 2025 during the presentation. An audio webcast will be available live and an archived version will be posted on the company's investor website for a limited time.
Positive
- None.
Negative
- None.
News Market Reaction – BMRN
On the day this news was published, BMRN declined 2.32%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Key biotech peers (e.g., EXEL, ASND, IONS, BBIO, SMMT) all showed positive price changes today, but no peers appeared in the momentum scanner, so BMRN’s 2.06% move is treated as stock-specific rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 19 | Strategic acquisition | Positive | +17.7% | All-cash Amicus acquisition to expand rare disease portfolio and revenues. |
| Nov 11 | Conference participation | Neutral | +4.3% | Investor presentation at Jefferies healthcare conference with webcast access. |
| Oct 29 | Regulatory update | Positive | -3.0% | FDA Priority Review acceptance for PALYNZIQ sBLA in adolescents with PKU. |
| Oct 29 | Earnings results | Negative | -3.3% | Q3 2025 revenue growth but GAAP loss and lower Non-GAAP EPS guidance. |
| Oct 22 | Earnings call notice | Neutral | +2.2% | Announcement of Q3 2025 results call and webcast scheduling details. |
BMRN has shown strong positive alignment on major strategic events like acquisitions, but more mixed or divergent reactions around clinical and earnings-related updates.
Over recent months, BioMarin reported Q3 2025 results with growing revenues but a GAAP loss driven by acquired R&D, and it reaffirmed key VOXZOGO guidance. The FDA’s Priority Review for PALYNZIQ’s label expansion and a planned divestiture of ROCTAVIAN highlighted pipeline and portfolio reshaping. A major acquisition of Amicus for about $4.8B was well received with a strong price gain. Prior conference participation news also coincided with modest positive moves, similar in nature to today’s JPM conference presentation and preliminary results notice.
Market Pulse Summary
This announcement highlights BioMarin’s upcoming presentation at the J.P. Morgan Healthcare Conference and plans to share preliminary financial results for the year ended December 31, 2025. Context from recent quarters includes revenue growth offset by GAAP losses tied to acquired R&D, as well as a sizeable rare-disease acquisition. Investors may monitor details of preliminary figures, integration progress, and any updated outlook shared during the January 12, 2026 presentation.
AI-generated analysis. Not financial advice.
An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael,
Contacts: | |
Investors | Media |
Traci McCarty | Marni Kottle |
BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
(415) 455-7558 | (650) 374-2803 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-on-monday-january-12-at-1115-am-pt--215-pm-et-in-san-francisco-ca-302656804.html
SOURCE BioMarin Pharmaceutical Inc.
FAQ
When will BioMarin (BMRN) present at the 44th Annual J.P. Morgan Healthcare Conference?
Who will present for BioMarin (BMRN) at the J.P. Morgan conference?
Will BioMarin (BMRN) release financial results at the J.P. Morgan presentation?
How can investors access BioMarin's (BMRN) J.P. Morgan presentation webcast?
Will BioMarin's (BMRN) J.P. Morgan presentation be available after the event?
